A review of the LexisNexis legal research database identified 21 medical liability cases involving GLP-1 receptor agonists through February 2026, with only six cases occurring since 2021. [1]
A press release from Eli Lilly reported that adults with moderate to severe psoriatic disease and overweight or obesity saw sustained or continued improvement in disease activity at 52 weeks with tirzepatide plus ixekizumab versus ixekizumab monotherapy. [2] Of the 15 cases before 2021, 10 involved failure-to-warn claims related to pancreatitis and pancreatic cancer, whereas the six newer cases involved allegations of commercial fraud or prescribing-related negligence. [3] In the TOGETHER-PsA trial, 39.2% of the combination group achieved the primary outcome of 50% or greater reduction in psoriatic arthritis disease activity based on American College of Rheumatology 50 plus at least 10% weight loss by week 52, compared to 1.7% in the monotherapy group. [4][5]Una revisión de la base de datos de investigación legal LexisNexis identificó 21 casos de responsabilidad médica que involucran agonistas del receptor GLP-1 hasta febrero de 2026, con solo seis casos ocurridos desde 2021. [1]
Un comunicado de prensa de Eli Lilly informó que los adultos con enfermedad psoriásica moderada a grave y sobrepeso u obesidad observaron una mejora sostenida o continua en la actividad de la enfermedad a las 52 semanas con tirzepatida más ixekizumab en comparación con ixekizumab en monoterapia. [2] De los 15 casos anteriores a 2021, 10 involucraron reclamos por falta de advertencia relacionados con pancreatitis y cáncer de páncreas, mientras que los seis casos más recientes involucrron alegaciones de fraude comercial o negligencia relacionada con la prescripción. [3] En el ensayo TOGETHER-PsA, el 39.2% del grupo de combinación logró el resultado primario de reducción del 50% o mayor en la actividad de la enfermedad de artritis psoriásica basada en el American College of Rheumatology 50 más al menos un 10% de pérdida de peso a la semana 52, en comparación con el 1.7% en el grupo de monoterapia. [4][5]
Proof5 sources · 2 publishers
What this stands on
A review of the LexisNexis legal research database identified 21 medical liability cases involving GLP-1 receptor agonists through February 2026, with only six cases occurring since 2021. · MedpageToday
A press release from Eli Lilly reported that adults with moderate to severe psoriatic disease and overweight or obesity saw sustained or continued improvement in disease activity at 52 weeks with tirzepatide plus ixekizumab versus ixekizumab monotherapy. · healio.com
Of the 15 cases before 2021, 10 involved failure-to-warn claims related to pancreatitis and pancreatic cancer, whereas the six newer cases involved allegations of commercial fraud or prescribing-related negligence. · MedpageToday
In the TOGETHER-PsA trial, 39.2% of the combination group achieved the primary outcome of 50% or greater reduction in psoriatic arthritis disease activity based on American College of Rheumatology 50 plus at least 10% weight loss by week 52, compared to 1.7% in the monotherapy group. · healio.com
In the TOGETHER-PsO trial, more than 40% of participants receiving combination therapy achieved complete skin clearance by week 52 versus 29.1% in the monotherapy group. · healio.com
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Tuesday, September 1, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.